We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Modafinil (Provigil) — wakefulness-promoting agent
A prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug.
Prescription medication — not a dietary supplement
Modafinil is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Modafinil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 271 participants.
Based on 40 studies · 11 meta-analyses · 17 RCTs · 3,883 total participants
Confidence
High confidenceBy outcome
Modafinil has strong pivotal-RCT evidence for its approved sleep-disorder indications (narcolepsy, shift-work sleep disorder, residual sleepiness in treated OSA), but the popular off-label cognitive-enhancement use is supported only by modest, task-dependent effects in healthy adults (largest meta-analysis overall effect ~0.12), it is not a longevity drug, and it carries a rare but serious skin-reaction (SJS/TEN) warning — so the off-label use stays emerging.
35 rigorous studies
19 randomized trials · 13 meta-analyses · 3 systematic reviews
Our evidence rating for Modafinil is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
14 trials ongoing or recruiting · 149 completed on ClinicalTrials.gov
76 of the completed trials have posted results
Registered trials show research momentum for Modafinil, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Modafinil is a eugeroic — a wakefulness-promoting agent — that increases cortical catecholamine tone and indirectly raises orexin, histamine, glutamate, and serotonin signalling while lowering GABA, producing alertness through a profile distinct from amphetamine.
Its approved uses are well-evidenced: pivotal placebo-controlled RCTs in narcolepsy (the US Modafinil in Narcolepsy trials), in shift-work sleep disorder (Czeisler, NEJM 2005), and as an adjunct for residual excessive sleepiness in CPAP-treated obstructive sleep apnea (Black & Hirshkowitz, 2005) all show significant reductions in objective and subjective sleepiness.
Off-prescription, modafinil is taken widely as a cognitive enhancer or 'smart drug', and this is where the honest distinction matters: systematic reviews and meta-analyses in healthy, non-sleep-deprived adults find the cognitive benefit is MODEST and TASK-DEPENDENT — most consistent for executive function, attention, and memory updating under demanding or sleep-deprived conditions, smaller and inconsistent for simple tasks, with the largest 2020 meta-analysis reporting an overall effect size of only ~0.12 and concluding the user perception of strong enhancement 'is not supported by the evidence.' Modafinil is not a longevity or healthspan drug — there is no lifespan or geroprotective evidence.
Its abuse and dependence liability is low relative to classic stimulants, but it is not benign: the label carries a boxed/serious warning for rare but life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis), plus psychiatric effects, and it induces CYP3A4 (reducing hormonal contraceptive efficacy).
The score reflects genuinely strong evidence for its approved sleep-disorder indications against a modest, task-dependent off-label cognitive benefit and real serious-rash risk.
Increases cortical catecholamine levels (weak dopamine-transporter inhibition raising synaptic dopamine and noradrenaline) — the core of its wake-promoting action.
Indirectly activates orexin (hypocretin) neurons and the tuberomammillary histamine system, engaging the brain's intrinsic arousal pathways.
Effects favour prefrontal-dependent processes — working/episodic memory and executive control — over subcortical sites, underlying the task-dependent cognitive effects.
How Modafinil works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use additional/alternative contraception during and for ~1 month after modafinil (CYP3A4 induction lowers efficacy).
Use with caution — modafinil can precipitate mania, psychosis, or anxiety.
Caution with uncontrolled hypertension or arrhythmia; monitor blood pressure and heart rate.
Modafinil induces CYP3A4 and can reduce contraceptive efficacy — additional/alternative contraception is advised during and for ~1 month after use.
Inhibits CYP2C19 and alters other enzymes — can raise levels of warfarin, phenytoin, and similar drugs; monitor.
Additive cardiovascular and CNS stimulation; use with caution.
Tip: Most frequent adverse effect in trials; often dose-related and transient.
Tip: Dose in the morning; reduce dose if sleep or anxiety is affected.
Tip: Stop immediately and seek emergency care at the first sign of rash, blistering, or mucosal involvement; risk is highest early in treatment.
Tip: Caution in those with a psychiatric history; discontinue and seek care if new psychiatric symptoms emerge.
Modafinil has an evidence score of 5/10 — moderate evidence based on 35 indexed studies, including 1 meta-analysis. A prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug. Representative study: PMID 32709551.
The commonly studied dose of Modafinil is Approved dosing is 200 mg once daily in the morning for narcolepsy and OSA, or 200 mg taken ~1 hour before the start of a night shift for shift-work sleep disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Modafinil is in the morning. It can be taken on an empty stomach. Long half-life (~12–15 h) means morning dosing avoids disrupting nighttime sleep; shift-work use is dosed before the shift.
Modafinil should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are headache, insomnia / anxiety / nervousness, serious skin reaction (Stevens-Johnson syndrome / TEN). Use caution if any of these apply to you: Prior hypersensitivity or serious skin reaction to modafinil/armodafinil; History of left ventricular hypertrophy or mitral valve prolapse with prior stimulant use; Uncontrolled hypertension or arrhythmia (use with caution).
Caffeine
Likely helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — one of the most proven ergogenic aids.
Citicoline
Probably helpsDual precursor to acetylcholine and phosphatidylcholine — enhances memory, focus, and brain cell membrane repair.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Theacrine
Mostly mechanism / observationalCaffeine-like purine alkaloid from kucha tea. Small RCTs suggest subjective energy and mood benefits and good safety, but objective performance gains are inconsistent.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Athletic Performance
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 40 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research